Stage 4 Cancer
Photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides This study is currently recruiting patients. Sponsors and Collaborators: Ireland Cancer Center and National Cancer Institute (NCI). This phase I trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.
Condition Treatment or Intervention Phase
Actinic keratosis Drug: silicon phthalocyanine 4 Phase I
Cutaneous T cell Procedure: cancer prevention intervention
lymphoma Procedure: chemoprevention of cancer
Skin cancer Procedure: laser therapy
Procedure: photodynamic therapy
Procedure: phototherapy
Study ID Numbers: CDR0000410675; CWRU-CASE-1Y04; CWRU-100301; NCT00103246
ClinicalTrials.gov Identifier: NCT00103246
COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group
|
